All dollar amounts stated herein are in U.S. dollars unless specified otherwise. Overview We are a pharmaceutical company developing a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors ...
Q2 FY2026 — expected 2026-09-20
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | INM | discussed_in_filing Artificial Intelligence | |
| topic_mention | INM | discussed_in_filing Cybersecurity | |
| topic_mention | INM | discussed_in_filing Trusted Computing | |
| topic_mention | INM | discussed_in_filing Blockchain & Crypto | |
| topic_mention | INM | discussed_in_filing Regulation | |
| topic_mention | INM | discussed_in_filing Healthcare & Bio | |
| topic_mention | INM | discussed_in_filing Platform & Ecosystem | |
| topic_mention | INM | discussed_in_filing Artificial Intelligence | |
| topic_mention | INM | discussed_in_filing Cybersecurity | |
| topic_mention | INM | discussed_in_filing Trusted Computing | |
| topic_mention | INM | discussed_in_filing Blockchain & Crypto | |
| topic_mention | INM | discussed_in_filing Regulation | |
| topic_mention | INM | discussed_in_filing Healthcare & Bio | |
| topic_mention | INM | discussed_in_filing Platform & Ecosystem | |
| topic_mention | INM | discussed_in_filing Artificial Intelligence | |
| topic_mention | INM | discussed_in_filing Cybersecurity | |
| topic_mention | INM | discussed_in_filing Trusted Computing | |
| topic_mention | INM | discussed_in_filing Blockchain & Crypto | |
| topic_mention | INM | discussed_in_filing Regulation | |
| topic_mention | INM | discussed_in_filing Healthcare & Bio |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-09-23 | 2025-06-30 | 0001213900-25-090210 | EDGAR | 75K words |
| 2024-09-30 | 2024-06-30 | 0001213900-24-082843 | EDGAR | — |
| 2023-09-29 | 2023-06-30 | 0001213900-23-080842 | EDGAR | — |
| 2022-09-23 | 2022-06-30 | 0001213900-22-058355 | EDGAR | — |
| 2021-09-24 | 2021-06-30 | 0001213900-21-049679 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-11 | 2025-12-31 | 0001213900-26-014996 | EDGAR | 22K words |
| 2025-11-06 | 2025-09-30 | 0001213900-25-107152 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001213900-25-042126 | EDGAR | — |
| 2025-02-12 | 2024-12-31 | 0001213900-25-013063 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001213900-24-098445 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001213900-24-042467 | EDGAR | — |
| 2024-02-13 | 2023-12-31 | 0001213900-24-013414 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001213900-23-086255 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001213900-23-039477 | EDGAR | — |
| 2023-02-17 | 2022-12-31 | 0001213900-23-012859 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001213900-22-071487 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001213900-22-026136 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001213900-26-039943 | EDGAR | 1K words |
| 2026-03-30 | 0001062993-26-001697 | EDGAR | — |
| 2026-03-23 | 0001062993-26-001567 | EDGAR | — |
| 2026-03-09 | 0001062993-26-001347 | EDGAR | — |
| 2026-03-06 | 0001213900-26-024752 | EDGAR | — |
| 2026-02-12 | 0001062993-26-000819 | EDGAR | — |
| 2025-12-18 | 0001062993-25-017390 | EDGAR | — |
| 2025-12-15 | 0001213900-25-121497 | EDGAR | — |
| 2025-11-19 | 0001213900-25-112644 | EDGAR | — |
| 2025-10-16 | 0001213900-25-099529 | EDGAR | — |
217 total filings indexed. 190 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001728328 |
| Ticker | INM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | A1 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report